FDA Warns Of Ibuprofen Interference With Aspirin Cardioprotection
This article was originally published in The Tan Sheet
Executive Summary
Ibuprofen 400 mg may interfere with the cardioprotective effect of uncoated low-dose (81 mg) aspirin when they are concomitantly dosed, FDA said in a Sept. 8 science paper
You may also be interested in...
EMA Scrutinizes Ibuprofen’s Cardiovascular Risk Potential
EMA’s Pharmacovigilance Risk Assessment Committee will recommend whether current contraindications, precautions and warnings relating to arterial thrombotic risk of ibuprofen at daily usage of 2,400 mg and up are adequate and whether updates to the product information or other regulatory measures are needed.
EMA Scrutinizes Ibuprofen’s Cardiovascular Risk Potential
EMA’s Pharmacovigilance Risk Assessment Committee will recommend whether current contraindications, precautions and warnings relating to arterial thrombotic risk of ibuprofen at daily usage of 2,400 mg and up are adequate and whether updates to the product information or other regulatory measures are needed.
Naproxen Fares Better Than Ibuprofen In Cardiovascular-Risk Data
Traditional non-selective NSAIDs, with the exception of naproxen, carry similar cardiovascular risk to COX-2 inhibitors, according to results of a study released by the Agency for Healthcare Research & Quality (AHRQ) Sept. 25